GERON CORP (GERN)

Geron to Announce First Quarter 2024 Financial Results on May 2, 2024

3 Red-Hot Biotech Rockets Blasting Off in 2024

The economy is looking very strong and the biotech industry even more so, thus consider these top three stocks for strong profits.

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron to Participate at Upcoming Investor Conferences in April

Interesting GERN Put And Call Options For August 16th

GERN May 3rd Options Begin Trading

Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Can Geron Corporation maintain momentum following FDA’s backing?

Friday saw an unprecedented surge in the stock of Geron Corporation (NASDAQ:GERN), with shares ending the day up a staggering 92%. This surge, marking a historic milestone for the company, was ignited by a momentous announcement earlier in the day. An FDA advisory committee’s resounding endorsement of Geron’s lead asset, Imetelstat, sent shockwaves through the […]

Friday Sector Leaders: Vehicle Manufacturers, Biotechnology Stocks

Why Is Geron (GERN) Stock Up 94% Today?

Geron stock is on the rise Friday with heavy trading of GERN shares after the company's blood disorder drug got new backing.

Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS

Noteworthy Tuesday Option Activity: GERN, NET, FSLR

Geron (GERN) Q4 2023 Earnings Call Transcript

GERN earnings call for the period ending December 31, 2023.

Geron GAAP EPS of -$0.09 beats by $0.01 (NASDAQ:GERN)

Geron Corporation reports positive Q4 earnings, beating expectations by $0.01.

Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

First Week of April 19th Options Trading For Geron (GERN)

Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

Commit To Buy Geron Corp. At $1.50, Earn 162.4% Annualized Using Options

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron to Participate in the B. Riley Securities Virtual Oncology Conference

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS

Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis

Geron shares rise after positive trial results of blood disorder candidate (NASDAQ:GERN)

Geron's stock rises on positive Phase 3 trial results for its myelodysplastic syndrome drug, imetelstat, potentially improving treatment for certain...